Scailyte and MaxiVAX proudly announce their collaboration to improve patient outcomes.
Scailyte and MaxiVAX, two cutting-edge precision medicine organizations, proudly announce their collaboration to improve patient outcomes.
Recognizing the potential of data-driven insights in informing and improving clinical outcomes, MaxiVAX sought a partner with expertise in data analytics. In this collaboration, Scailyte conducted a retrospective multi-omic analysis of phase IIa clinical single arm trial data for MaxiVAX’s lead cancer vaccine candidate, with the goal of characterizing the biological determinants of patient response.
By integrating advanced data analytics into MaxiVAX clinical programs, the collaboration has yielded valuable insights that shed light on the benefit:risk ratio of their clinical candidate, supporting decisions related to the clinical development of this molecule.
“Scailyte has deployed advanced AI and analytics to key clinical data, with the aim of unveiling relevant insights to support MaxiVAX’ decisions on the next development milestones,” said Corinne Solier, SVP Corporate & Technology Development at Scailyte. “With a commitment to scientific rigor and excellence, this partnership exemplified the power of data-driven decision-making”.
“Scailyte has been instrumental in analyzing phase IIa clinical single arm trial data of our most advanced development program” said Thomas Mehrling, MD PhD, CEO of MaxiVAX. “Scailyte’s scientific expertise, communication style and agility are commendable”, added Thomas.
Moving forward, Scailyte and MaxiVAX remain committed to pushing the boundaries of innovation and unlocking the potential of data-driven healthcare for the betterment of patient prognoses.
About Scailyte
Scailyte is a Swiss-based start-up specialized in generating actionable insights/biosignatures from multi-omics single-cell data using artificial intelligence (AI). Our AI platform, ScaiVision, combines features to integrate different datasets, is indication- and cell-type agnostic and uses data augmentation and a cluster-free approach to extract relevant information while retaining single-cell resolution. These features result in very high discovery success rates from a limited number of samples, with actionable insights for the basis of assay development.
With a commitment to excellence, Scailyte empowers partners to transform data into actionable intelligence informing decision making and driving innovation.
For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.
ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.
About MaxiVAX
MaxiVAX is a clinical-stage biotechnology company advancing patient-specific immunomodulatory strategies for the treatment of cancers. The company was founded in 2005 and is dedicated to efficiently progressing potential best-in-class anti-cancer immunotherapies to address significant unmet medical needs and improve outcomes for people with difficult-to-treat cancer.
For more information, visit www.maxivax.ch and connect on @LinkedIn.
Recent News
Transforming Healthcare with Unmatched Biomarker Discovery Power
Experience the game-changing convergence of AI and healthcare. Join us on this journey as we transla...
Recent News
LSX Congress USA 2023
Join Scailyte at the LSX Congress USA in Boston on September 13-14 at the Hynes Convention Centre, B...
Recent News
Unveiling ScaiVision's Clinical Potential
Embarking on the last leg of our Discovery Potential series, we're delving into ScaiVision's incredi...
Recent News
ScaiDigest Volume 3: Unveiling Immuno-Oncology's Next Frontier
In Volume 3, our very own Diana Stoycheva takes the helm to explore the fascinating realm of single-...
Recent News
Revolutionizing Biomarker Discovery: Unlock the Power of Scailyte's AI platform
Dive into the forefront of scientific advancement with Scailyte's groundbreaking AI platform, ScaiVi...
Recent News
Empowering Precision Healthcare with Unparalleled Discovery Potential
From revealing hidden insights to transforming healthcare, ScaiVision is rewriting the rules of disc...
Recent News
Accelerating Discoveries with Scailyte's Speed Strength
In the world of clinical research and development, time is of the essence. Our mission at Scailyte i...
Recent News
Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth
At Scailyte, our commitment to ESG goes beyond numbers. It extends to every individual within our vi...
Recent News
Transforming Healthcare with Unmatched Biomarker Discovery Power
Experience the game-changing convergence of AI and healthcare. Join us on this journey as we transla...
LSX Congress USA 2023
Join Scailyte at the LSX Congress USA in Boston on September 13-14 at the Hynes Convention Centre, B...
Recent News
Unveiling ScaiVision's Clinical Potential
Embarking on the last leg of our Discovery Potential series, we're delving into ScaiVision's incredi...
ScaiDigest Volume 3: Unveiling Immuno-Oncology's Next Frontier
In Volume 3, our very own Diana Stoycheva takes the helm to explore the fascinating realm of single-...
Recent News
Revolutionizing Biomarker Discovery: Unlock the Power of Scailyte's AI platform
Dive into the forefront of scientific advancement with Scailyte's groundbreaking AI platform, ScaiVi...
Empowering Precision Healthcare with Unparalleled Discovery Potential
From revealing hidden insights to transforming healthcare, ScaiVision is rewriting the rules of disc...
Recent News
Accelerating Discoveries with Scailyte's Speed Strength
In the world of clinical research and development, time is of the essence. Our mission at Scailyte i...
Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth
At Scailyte, our commitment to ESG goes beyond numbers. It extends to every individual within our vi...